Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 11/20 | 0.75 |
| ▸ | PTGER2 | P43116 | 9/20 | 0.75 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711255 | 1.00 | PTGER4 (1.00) | PTGER4PTGER3PTGER2PTGER1KCNH2 | |
| SCHEMBL6710568 | 0.86 | PTGER4 (0.74) | PTGER4PTGER3PTGER2PTGER1KCNH2 | |
| SCHEMBL6710566 | 0.86 | PTGER4 (0.74) | PTGER4PTGER3PTGER2PTGER1KCNH2 | |
| SCHEMBL5733514 | 0.79 | PTGER4 (1.00) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL5733519 | 0.79 | PTGER4 (1.00) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL11830499 | 0.79 | PTGER4 (1.00) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6609053 | 0.79 | PTGER4 (1.00) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL5733516 | 0.79 | PTGER4 (1.00) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL5733521 | 0.79 | PTGER4 (1.00) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL11830503 | 0.79 | PTGER4 (1.00) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | claimed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254230-A1 | Method for treating ocular hypertension | PTGIR, PTGER4, PTGER1 | PTGER4 2/4885PTGER3 5/4885PTGER2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.